Trial Profile
Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Levofolinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms VESTIGE
- 06 Sep 2023 This study has been completed in Belgium and Norway, according to European Clinical Trials Database.
- 07 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 27 May 2022 Planned primary completion date changed from 1 Apr 2023 to 1 Sep 2023.